NTRK1 and cholangiocarcinoma: In our screening of receptor tyrosine kinase inhibitors on the KKU-M213 cell line, ceritinib emerged as the most cytotoxic compound among 112 RTK inhibitors, prompting further exploration of its therapeutic potential in CCA.